Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Mayumi Nakagawa

TitleProfessor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentPathology, College of Medicine
DivisionPathology Clinical
AddressM1/321 Central Building (old hospital)
4301 W.Markham
Mail Slot # 502
Little Rock AR 72205
Phone501-686-8635
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    2R01CA143130     (GREENFIELD, WILLIAM W)Jul 1, 2021 - Jun 30, 2026
    NIH/Nat. Cancer Institute
    Understanding and Enhancing T-Cell Responses to High Risk Human Papillomaviruses-Renewal
    Role: Principal Investigator
    2R01CA143130-11A1     (GREENFIELD, WILLIAM W)Jul 1, 2021 - Jun 30, 2026
    NIH/Nat. Cancer Institute
    Understanding and Enhancing T-Cell Responses to High Risk Human Papillomaviruses-Renewal
    Role: Principal Investigator
    RO1CA143130     (GREENFIELD, WILLIAM W)Jul 1, 2021 - Jun 30, 2026
    NIH/Nat. Cancer Institute
    Understanding and Enhancing T-Cell Responses to High Risk Human Papillomaviruses-Renewal
    Role: Principal Investigator
    CI-Cancer Prevention & Population Program     (NAKAGAWA, MAYUMI)Oct 1, 2016 - Sep 30, 2017
    UAMS
    Nakagawa_CPPS Pilot Award
    Role: Principal Investigator
    CI-CancerPrevention&PopulationProgram     (NAKAGAWA, MAYUMI)Oct 1, 2016 - Sep 30, 2017
    UAMS
    Nakagawa_CPPS Pilot Award
    Role: Principal Investigator
    P20GM103625     (SMELTZER, MARK S)Aug 15, 2012 - Apr 30, 2022
    NIH
    Center for Microbial Pathogenesis and Host Inflammatory Responses
    Role: Co-Investigator
    R01CA143130     (NAKAGAWA, MAYUMI)Jul 1, 2010 - Jun 30, 2026
    NIH
    Understanding and Enhancing T-Cell Responses to High Risk Human Papillomaviruses-Renewal
    Role: Principal Investigator
    RSG-06-180-01-MBC     (NAKAGAWA, MAYUMI)Jul 1, 2006 - Dec 31, 2010
    American Cancer Society, Inc.
    CD8 T-cell epitopes of high risk human papillomaviruses
    Role: Principal Investigator
    RSG-06-180-01-MSC     (NAKAGAWA, MAYUMI)Jul 1, 2006 - Dec 31, 2010
    American Cancer Society, Inc.
    CD8 T-cell epitopes of high risk human papillomaviruses
    Role: Principal Investigator
    R37CA051323     (NAKAGAWA, MAYUMI)Sep 10, 2005 - Jun 30, 2010
    NIH/Nat. Cancer Institute - Pass Through: University of California, San Francisco
    Natural History of HPV Infection to Neoplasia (Subcontract with UCSF 4166sc)
    Role: Principal Investigator
    R01CA087905     (NAKAGAWA, MAYUMI)May 1, 2005 - May 19, 2006
    NIH/Nat. Cancer Institute - Pass Through: University of California, San Francisco
    History of CIN-2 in Adolescents (Subcontract with UCSF 4023sc)
    Role: Principal Investigator
    R01CA051323     (NAKAGAWA, MAYUMI)Sep 1, 2004 - Aug 31, 2006
    NIH/Nat. Cancer Institute - Pass Through: University of California, San Francisco
    Natural History of HPV-Infection to Neoplasia
    Role: Principal Investigator
    RSG     (MACNICOL, ANGUS)Mar 1, 2002 - Feb 28, 2006
    American Cancer Society, Inc.
    MRNA translational Control of Cell Cycle Progression
    Role: Principal Investigator
    K07CA075974     (NAKAGAWA, MAYUMI)Feb 1, 1998 - Jan 31, 2004
    NIH
    CYTOTOXIC T LYMPHOCYTE RESPONSE TO HPV 16
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Dai L, Wilson LG, Nakagawa M, Qin Z. Coinfections with additional oncoviruses in HPV+ individuals: Status, function and potential clinical implications. J Med Virol. 2024 Jan; 96(1):e29363. PMID: 38178584.
      View in: PubMed
    2. Shibata T, Shah S, Evans T, Coleman H, Lieblong BJ, Spencer HJ, Quick CM, Sasagawa T, Stephens OW, Peterson E, Johann D, Lu YC, Nakagawa M. Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed. Front Immunol. 2021; 12:645299. PMID: 34659195.
      View in: PubMed
    3. Shibata T, Nakagawa M, Coleman HN, Owens SM, Greenfield WW, Sasagawa T, Robeson MS. Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota. PLoS One. 2021; 16(8):e0237556. PMID: 34460815.
      View in: PubMed
    4. Matsumoto T, Oda Y, Hasegawa Y, Hashimura M, Oguri Y, Inoue H, Yokoi A, Tochimoto M, Nakagawa M, Jiang Z, Saegusa M. Anaplastic Lymphoma Kinase Overexpression Is Associated with Aggressive Phenotypic Characteristics of Ovarian High-Grade Serous Carcinoma. Am J Pathol. 2021 10; 191(10):1837-1850. PMID: 34214505.
      View in: PubMed
    5. Shah SK, Jones-Carr M, Bimali M, Su LJ, Nakagawa M. An Online Survey and Focus Groups for Promoting Cancer Prevention Measures. J Cancer Educ. 2022 12; 37(6):1782-1789. PMID: 34046818.
      View in: PubMed
    6. Shah SK, Demmings BE, Bimali M, Hadden K, Nakagawa M. Assessing the Feasibility of an Online Module for Promoting Cancer Prevention Measures. Cancer Control. 2021 Jan-Dec; 28:10732748211037908. PMID: 34794322.
      View in: PubMed
    7. Matsumoto T, Chino H, Akiya M, Hashimura M, Yokoi A, Tochimoto M, Nakagawa M, Jiang Z, Saegusa M. Requirements of LEFTY and Nodal overexpression for tumor cell survival under hypoxia in glioblastoma. Mol Carcinog. 2020 12; 59(12):1409-1419. PMID: 33111989.
      View in: PubMed
    8. Shah SK, Nakagawa M, Lieblong BJ. Examining aspects of successful community-based programs promoting cancer screening uptake to reduce cancer health disparity: A systematic review. Prev Med. 2020 12; 141:106242. PMID: 32882299.
      View in: PubMed
    9. Wongsurawat T, Nakagawa M, Atiq O, Coleman HN, Jenjaroenpun P, Allred JI, Trammel A, Puengrang P, Ussery DW, Nookaew I. An assessment of Oxford Nanopore sequencing for human gut metagenome profiling: A pilot study of head and neck cancer patients. J Microbiol Methods. 2019 11; 166:105739. PMID: 31626891.
      View in: PubMed
    10. Shibata T, Lieblong BJ, Sasagawa T, Nakagawa M. The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer. Cancer Treat Rev. 2019 Aug; 78:8-16. PMID: 31302573.
      View in: PubMed
    11. Lieblong BJ, Montgomery BEE, Su LJ, Nakagawa M. Natural history of human papillomavirus and vaccinations in men: A literature review. Health Sci Rep. 2019 May; 2(5):e118. PMID: 31139757.
      View in: PubMed
    12. Kamiya T, Hira D, Hoshino N, Kurihara M, Nakagawa M, Sasaki M, Terada T. Low Body Mass Index and Myeloablative Conditioning Regimen Prolong the Duration of Parenteral Nutrition During Hematopoietic Stem Cell Transplantation. Ann Nutr Metab. 2019; 74(2):107-114. PMID: 30673667.
      View in: PubMed
    13. Ravilla R, Coleman HN, Chow CE, Chan L, Fuhrman BJ, Greenfield WW, Robeson MS, Iverson K, Spencer H, Nakagawa M. Cervical Microbiome and Response to a Human Papillomavirus Therapeutic Vaccine for Treating High-Grade Cervical Squamous Intraepithelial Lesion. Integr Cancer Ther. 2019 Jan-Dec; 18:1534735419893063. PMID: 31833799.
      View in: PubMed
    14. Abdallah AO, Coleman H, Kamel M, Davis R, Landrum T, Spencer H, Mackintosh S, Mahmoud FA, Milojkovic N, Wicker C, Arnaoutakis K, Nakagawa M. A novel prostate cancer immunotherapy using prostate-specific antigen peptides and Candida skin test reagent as an adjuvant. SAGE Open Med. 2018; 6:2050312118800202. PMID: 30245818.
      View in: PubMed
    15. Ou Y, Cannon MJ, Nakagawa M. Regulatory T Cells in Gynecologic Cancer. MOJ Immunol. 2018; 6(2):34-42. PMID: 30637330.
      View in: PubMed
    16. Wang X, Che Y, Chen B, Zhang Y, Nakagawa M, Wang X. Evaluation of immune responses induced by a novel human papillomavirus type 16 E7 peptide-based vaccine with Candida skin test reagent as an adjuvant in C57BL/6 mice. Int Immunopharmacol. 2018 Mar; 56:249-260. PMID: 29414659.
      View in: PubMed
    17. Coleman HN, Greenfield WW, Stratton SL, Vaughn R, Kieber A, Moerman-Herzog AM, Spencer HJ, Hitt WC, Quick CM, Hutchins LF, Mackintosh SG, Edmondson RD, Erickson SW, Nakagawa M. Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination. Cancer Immunol Immunother. 2016 May; 65(5):563-73. PMID: 26980480.
      View in: PubMed
    18. Moerman-Herzog A, Nakagawa M. Early Defensive Mechanisms against Human Papillomavirus Infection. Clin Vaccine Immunol. 2015 Aug; 22(8):850-7. PMID: 26063238.
      View in: PubMed
    19. Greenfield WW, Stratton SL, Myrick RS, Vaughn R, Donnalley LM, Coleman HN, Mercado M, Moerman-Herzog AM, Spencer HJ, Andrews-Collins NR, Hitt WC, Low GM, Manning NA, McKelvey SS, Smith D, Smith MV, Phillips AM, Quick CM, Jeffus SK, Hutchins LF, Nakagawa M. A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3. Oncoimmunology. 2015 Oct; 4(10):e1031439. PMID: 26451301.
      View in: PubMed
    20. Nakagawa M, Greenfield W, Moerman-Herzog A, Coleman HN. Cross-Reactivity, Epitope Spreading, and De Novo Immune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic Vaccines. Clin Vaccine Immunol. 2015 Jul; 22(7):679-87. PMID: 25947147.
      View in: PubMed
    21. Stratton SL, Spencer HJ, Greenfield WW, Low G, Hitt WC, Quick CM, Jeffus SK, Blackmon V, Nakagawa M. A novel use of a statewide telecolposcopy network for recruitment of participants in a Phase I clinical trial of a human papillomavirus therapeutic vaccine. Clin Trials. 2015 Jun; 12(3):199-204. PMID: 25576067.
      View in: PubMed
    22. Pandey S, Nakagawa M, Rosenbaum ER, Arnaoutakis K, Hutchins LF, Makhoul I, Milojkovic N, Cottler-Fox M. Rituximab and intermediate-purity plasma-derived factor VIII concentrate (Koate?) as adjuncts to therapeutic plasma exchange for thrombotic thrombocytopenic purpura in patients with an ADAMTS13 inhibitor. J Clin Apher. 2015 Feb; 30(1):50-4. PMID: 25042026.
      View in: PubMed
    23. Batra A, Cottler-Fox M, Harville T, Rhodes-Clark BS, Makhoul I, Nakagawa M. Autologous Graft versus Host Disease: An Emerging Complication in Patients with Multiple Myeloma. Bone Marrow Res. 2014; 2014:891427. PMID: 24876970.
      View in: PubMed
    24. Coleman HN, Wang X, Greenfield WW, Nakagawa M. A Human Papillomavirus Type 16 E6 52-62 CD4 T-Cell Epitope Restricted by the HLA-DR11 Molecule Described in an Epitope Hotspot. MOJ Immunol. 2014; 1(3). PMID: 25685851.
      View in: PubMed
    25. Nakagawa M, Coleman HN, Wang X, Daniels J, Sikes J, Nagarajan UM. IL-12 secretion by Langerhans cells stimulated with Candida skin test reagent is mediated by dectin-1 in some healthy individuals. Cytokine. 2014 Feb; 65(2):202-9. PMID: 24301038.
      View in: PubMed
    26. Wang X, Coleman HN, Nagarajan U, Spencer HJ, Nakagawa M. Candida skin test reagent as a novel adjuvant for a human papillomavirus peptide-based therapeutic vaccine. Vaccine. 2013 Dec 02; 31(49):5806-13. PMID: 24135577.
      View in: PubMed
    27. Nakagawa M, Spencer HJ, Coleman HN, Greenfield WW. Distribution of human papillomavirus (HPV) types and anti-HPV T-cell immune responses among different racial/ethnic groups in Central Arkansas. J Ark Med Soc. 2013 Jan; 109(8):160-3. PMID: 23367687.
      View in: PubMed
    28. Post GR, James L, Alapat D, Guillory V, Cottler-Fox M, Nakagawa M. A case of acquired dysfibrinogenemia in multiple myeloma treated with therapeutic plasma exchange. Transfus Apher Sci. 2013 Feb; 48(1):35-8. PMID: 22842111.
      View in: PubMed
    29. Wang X, Greenfield WW, Coleman HN, James LE, Nakagawa M. Use of interferon-? enzyme-linked immunospot assay to characterize novel T-cell epitopes of human papillomavirus. J Vis Exp. 2012 Mar 08; (61). PMID: 22434036.
      View in: PubMed
    30. Coleman HN, Moscicki AB, Farhat SN, Gupta SK, Wang X, Nakagawa M. CD8 T-cell responses in incident and prevalent human papillomavirus types 16 and 18 infections. ISRN Obstet Gynecol. 2012; 2012:854237. PMID: 22523697.
      View in: PubMed
    31. Kim KH, Greenfield WW, Cannon MJ, Coleman HN, Spencer HJ, Nakagawa M. CD4+ T-cell response against human papillomavirus type 16 E6 protein is associated with a favorable clinical trend. Cancer Immunol Immunother. 2012 Jan; 61(1):63-70. PMID: 21842207.
      View in: PubMed
    32. Kim KH, Horn TD, Pharis J, Kincannon J, Jones R, O'Bryan K, Myers J, Nakagawa M. Phase 1 clinical trial of intralesional injection of Candida antigen for the treatment of warts. Arch Dermatol. 2010 Dec; 146(12):1431-3. PMID: 21173332.
      View in: PubMed
    33. Veeraputhiran M, Ware J, Dent J, Bornhorst J, Post G, Cottler-Fox M, Pesek G, Theus J, Nakagawa M. A comparison of washed and volume-reduced platelets with respect to platelet activation, aggregation, and plasma protein removal. Transfusion. 2011 May; 51(5):1030-6. PMID: 20946201.
      View in: PubMed
    34. Kim KH, Horn, T, Pharis, J, Kincannon, J, Jones, R, O'Bryan, K, Myers, J, Nakagawa M. Phase I clinical trial of intralesional injection of Candida antigen for treating warts. 2010.
    35. Nakagawa M, Gupta SK, Coleman HN, Sellers MA, Banken JA, Greenfield WW. A favorable clinical trend is associated with CD8 T-cell immune responses to the human papillomavirus type 16 e6 antigens in women being studied for abnormal pap smear results. J Low Genit Tract Dis. 2010 Apr; 14(2):124-9. PMID: 20354421.
      View in: PubMed
    36. Kim, KH, Horn, T, Pharis, J, Kincannon, J, Jones, R, O'Bryan, K, Myers, J, Nakagawa M. Phase I clinical trial of intralesional injection of Candida antigen for treating warts. 2010.
    37. Nakagawa M, Gupta S, Coleman, H, Sellers, M, Banken, J, Greenfield, W. A favorable clinical trend is associated with CD8 T-Cell Responses to the Human papillomavirus Type 16 E6 Antigens in women being studied for abnormal Pap smear results. Journal of Lower Genital Tract Disease. 2010; 14:124-129.
    38. Farhat S, Nakagawa M, Moscicki A. Cell-meidated immune responses to humanpapillomavirus 16 E6 nad E7 antigens as measured by IFN gamma ELISpot in women woth cleared or persistent HPV infection. 2009; 19(4):508-12.
    39. Farhat S, Nakagawa M, Moscicki AB. Cell-mediated immune responses to human papillomavirus 16 E6 and E7 antigens as measured by interferon gamma enzyme-linked immunospot in women with cleared or persistent human papillomavirus infection. Int J Gynecol Cancer. 2009 May; 19(4):508-12. PMID: 19509544.
      View in: PubMed
    40. Farhat, S, Nakagawa M. Cell-mediated immune reponses to humanpapillomavirus 16 E6 and E7 antigens as measured by IFN gamma ELISpot in women with cleared or persistent HPV infection. Int Journal of Gynecological Cancer. 2009; (19):508-512.
    41. Farhat, S, Nakagawa M, Moscicki, A. -B Cell-mediated immune reponses to human papillomavirus 16 E6 and E7 antigens as measured by IFN gamma ELISpot in women with cleared or persistent HPV infection. International Journal of Gynecological Cancer. 2009; (19):508-512.
    42. Nakagawa, M, Gupta, S, Coleman, H, Sellers, M, Banken, J, Greenfield, W. Regression is Associated with CD8 T-Cell Responses to the Human Papillomavirus Type 16 E6. 2009.
    43. Wang X, Santin AD, Bellone S, Gupta S, Nakagawa M. A novel CD4 T-cell epitope described from one of the cervical cancer patients vaccinated with HPV 16 or 18 E7-pulsed dendritic cells. Cancer Immunol Immunother. 2009 Feb; 58(2):301-8. PMID: 18446336.
      View in: PubMed
    44. Wang X, Moscicki AB, Tsang L, Brockman A, Nakagawa M. Memory T cells specific for novel human papillomavirus type 16 (HPV16) E6 epitopes in women whose HPV16 infection has become undetectable. Clin Vaccine Immunol. 2008 Jun; 15(6):937-45. PMID: 18448624.
      View in: PubMed
    45. Wang X, Moscicki AB, Tsang L, Brockman A, Nakagawa M. Memory T-Cells Specific for Novel HPV 16 E6 Epitopes in Women Whose HPV 16 Infection Has Become Undetectable. Clin Vaccine Immunol. 2008.
    46. Kim KH, Greenfield W, Shotts E, Nakagawa M. Detection of human papillomavirus type 16-specific T lymphocytes by a recombinant vaccinia virus-based enzyme-linked immunospot assay. Clin Vaccine Immunol. 2007 Apr; 14(4):362-8. PMID: 17314231.
      View in: PubMed
    47. Farhat S, Nakagawa M, Kim KH, Moscicki AB. A comparison between gamma interferon ELISPOT and chromium release assays to detect cell-mediated immune responses to human papillomavirus type 16 E6 and E7 antigens. 2007; In Preparation.
    48. Nakagawa M, Kim KH, Gillam TM, Moscicki AB. HLA class I binding promiscuity of the CD8 T-cell epitopes of human papillomavirus type 16 E6 protein. J Virol. 2007 Feb; 81(3):1412-23. PMID: 17108051.
      View in: PubMed
    49. Kim KH, Dishongh R, Santin AD, Cannon MJ, Bellone S, Nakagawa M. Recognition of a cervical cancer derived tumor cell line by a human papillomavirus type 16 E6 52-61-specific CD8 T cell clone. Cancer Immun. 2006 Jun 30; 6:9. PMID: 16808432.
      View in: PubMed
    50. Nakagawa M, Kim KH, Moscicki AB. Patterns of CD8 T-cell epitopes within the human papillomavirus type 16 (HPV 16) E6 protein among young women whose HPV 16 infection has become undetectable. Clin Diagn Lab Immunol. 2005 Aug; 12(8):1003-5. PMID: 16085919.
      View in: PubMed
    51. Tugizov S, Berline J, Herrera R, Penaranda ME, Nakagawa M, Palefsky J. Inhibition of human papillomavirus type 16 E7 phosphorylation by the S100 MRP-8/14 protein complex. J Virol. 2005 Jan; 79(2):1099-112. PMID: 15613338.
      View in: PubMed
    52. Toy P, Hollis-Perry KM, Jun J, Nakagawa M. Recipients of blood from a donor with multiple HLA antibodies: a lookback study of transfusion-related acute lung injury. Transfusion. 2004 Dec; 44(12):1683-8. PMID: 15584980.
      View in: PubMed
    53. Nakagawa M, Toy P. Acute and transient decrease in neutrophil count in transfusion-related acute lung injury: cases at one hospital. Transfusion. 2004 Dec; 44(12):1689-94. PMID: 15584981.
      View in: PubMed
    54. Nakagawa M, Dempsey DA, Haller C, Toy P. Safe lead levels: blood transfusion of extremely low birth weight infants. Clin Pediatr (Phila). 2004 Sep; 43(7):681. PMID: 15378161.
      View in: PubMed
    55. Nakagawa M, Kim KH, Moscicki AB. Different methods of identifying new antigenic epitopes of human papillomavirus type 16 E6 and E7 proteins. Clin Diagn Lab Immunol. 2004 Sep; 11(5):889-96. PMID: 15358648.
      View in: PubMed
    56. Nakagawa M, Viscidi R, Deshmukh I, Costa MD, Palefsky JM, Farhat S, Moscicki AB. Time course of humoral and cell-mediated immune responses to human papillomavirus type 16 in infected women. Clin Diagn Lab Immunol. 2002 Jul; 9(4):877-82. PMID: 12093689.
      View in: PubMed
    57. Scott M, Nakagawa M, Moscicki AB. Cell-mediated immune response to human papillomavirus infection. Clin Diagn Lab Immunol. 2001; 8(2):209 - 220.
    58. Nakagawa M, Stites DP, Patel S, Farhat S, Scott M, Hills NK, Palefsky JM, Moscicki AB. Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens. J Infect Dis. 2000; 182(2):595 - 598.
    59. De JA, Palefsky JM, Stites DP, Nakagawa M. Human immunodeficiency virus-positive individuals with oral hairy leukoplakia are able to mount cytotoxic T lymphocyte responses to Epstein-Barr virus. Oral Dis. 2000; 6(1):40 - 47.
    60. Nakagawa M, Stites DP, Palefsky JM, Kneass Z, Moscicki AB. CD4-positive and CD8-positive cytotoxic T lymphocytes contribute to human papillomavirus type 16 E6 and E7 responses. Clin Diagn Lab Immunol. 1999; 6(4):494 - 498.
    61. Nakagawa M, Stites DP, Farhat S, Sisler JR, Moss B, Kong F, Moscicki AB, Palefsky JM. Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia. J Infect Dis. 1997; 175(4):927 - 931.
    62. Gniewek RA, Stites DP, McHugh TM, Hilton JF, Nakagawa M. Comparison of antinuclear antibody testing methods: immunofluorescence assay versus enzyme immunoassay. Clin Diagn Lab Immunol. 1997; 4(2):185 - 188.
    63. Nakagawa M, Stites DP, Farhat S, Judd A, Moscicki AB, Canchola AJ, Hilton JF, Palefsky JM. T-cell proliferative response to human papillomavirus type 16 peptides: relationship to cervical intraepithelial neoplasia. Clin Diagn Lab Immunol. 1996; 3(2):205 - 210.
    64. Zeff RA, Nakagawa M, Mashimo H, Gopas J, Nathenson SG. Failure of cell surface expression of a class I major histocompatibility antigen caused by somatic point mutation. Transplantation. 1990; 49(4):803 - 808.
    65. Ajitkumar P, Geier SS, Kesari KV, Borriello F, Nakagawa M, Bluestone JA, Saper MA, Wiley DC, Nathenson SG. Evidence that multiple residues on both the alpha-helices of the class I MHC molecule are simultaneously recognized by the T cell receptor. Cell. 1988; 54(1):47 - 56.
    66. Geliebter J, Ajit Kumar P, Boriello F, Hemmi S, Kesari K, Mashimo H, McGovern D, Nakagawa M, Palmieri-Lehner E, Pontarotti P, Pfaffenbach GM, Raval R, Trohnacki J, Zeff RA, Nathenson SG. Polymorphism and diversity in the murine class I gene family: A study of spontaneous mutants. Evolution and Vertebrate Immunity: The antigen-receptor and MHC gene families. 1987; 315-328.
    67. Zeff RA, Ajit Kumar P, Mashimo H, Nakagawa M, McCue B, Borriello F, Kesari K, Geliebter M, Hemmi S, Pfaffenbach G, Trohnacki J, McGovern D, Nathenson SG. Somatic cell variants of the murine major histocompatibility complex. Immunological Res. 1987; 6:133-144.
    68. Geliebter J, Ajit Kumar P, Borriello F, Hemmi S, Kesari K, Mashimo H, McCue B, Nakagawa M, Pfaffenbach GM, Zeff RA, Nathenson SG. Diversification of H-2 genes through recombination: A study of Kb mutants. Progress in Immunology VI. 1987; 186-196.
    69. Geliebter J, Ajit Kumar P, Borriello G, Hemmi S, Kaseri K, Mashimo H, Nakagawa M, Pontarotti P, Pfaffenbach GM, Zeff RA, Nathenson SG. The use of Class I mutants to study polymorphosm and diversity in the MHC. Perspectives in Immunogenetics and Histocompatibility. 1987; 7:43-50.
    70. Nakagawa M, Zeff RA, Geier SS, Bluestone JA, Nathenson SG. Somatic cell variants of H-2Kb: a point mutation in the first extracellular domain results in altered immune recognition. Immunogenetics. 1986; 24(6):381 - 385.
    71. Nathenson SG, Geliebter J, Geier SS, Mashimo H, Hemmi S, Kumar A, McGovern D, Nakagawa M, Pfaffenbach G, Pontatotti P, Zeff R. The study of H-2 major histocompatibility complex mutants reveals structure-function relationships and mechanisms of generation of diversity and polymorphism. ICSU Short Report, Advances in Gene Technology: Molecular Biology of the Immune System. 1985; 37-40.
    Nakagawa's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (217) concept(s)
    _
    Co-Authors Expand Description
    See all (27) people
    _
    Similar People Expand Description
    See all (31) people
    _
    Same Department Expand Description
    Search Department